Pub. Date : 2022 Jun 14
PMID : 35377947
1 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Here we report extended long-term follow-up from the RESONATE-2 phase 3 study of the once-daily Bruton"s tyrosine kinase inhibitor ibrutinib, which is the only targeted therapy with significant progression-free survival (PFS) and overall survival (OS) benefit in multiple randomized phase 3 CLL studies. | ibrutinib | Bruton tyrosine kinase | Homo sapiens |